210 related articles for article (PubMed ID: 33632467)
1. Protein kinase CK2 inhibition as a pharmacological strategy.
Borgo C; Ruzzene M
Adv Protein Chem Struct Biol; 2021; 124():23-46. PubMed ID: 33632467
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase CK2: a potential therapeutic target for diverse human diseases.
Borgo C; D'Amore C; Sarno S; Salvi M; Ruzzene M
Signal Transduct Target Ther; 2021 May; 6(1):183. PubMed ID: 33994545
[TBL] [Abstract][Full Text] [Related]
3. CK2 inhibition with silmitasertib promotes methuosis-like cell death associated to catastrophic massive vacuolization of colorectal cancer cells.
Silva-Pavez E; Villar P; Trigo C; Caamaño E; Niechi I; Pérez P; Muñoz JP; Aguayo F; Burzio VA; Varas-Godoy M; Castro AF; Colombo MI; Tapia JC
Cell Death Dis; 2019 Jan; 10(2):73. PubMed ID: 30683840
[TBL] [Abstract][Full Text] [Related]
4. Regulation of TMEM16A by CK2 and Its Role in Cellular Proliferation.
Pinto MC; Schreiber R; Lerias J; Ousingsawat J; Duarte A; Amaral M; Kunzelmann K
Cells; 2020 May; 9(5):. PubMed ID: 32380794
[TBL] [Abstract][Full Text] [Related]
5. Small molecule modulators targeting protein kinase CK1 and CK2.
Qiao Y; Chen T; Yang H; Chen Y; Lin H; Qu W; Feng F; Liu W; Guo Q; Liu Z; Sun H
Eur J Med Chem; 2019 Nov; 181():111581. PubMed ID: 31400711
[TBL] [Abstract][Full Text] [Related]
6. Contribution of the CK2 Catalytic Isoforms α and α' to the Glycolytic Phenotype of Tumor Cells.
Zonta F; Borgo C; Quezada Meza CP; Masgras I; Rasola A; Salvi M; Pinna LA; Ruzzene M
Cells; 2021 Jan; 10(1):. PubMed ID: 33477590
[TBL] [Abstract][Full Text] [Related]
7. Intracellular protein kinase CK2 inhibition by ferulic acid-based trimodal nanodevice.
Zanin S; Molinari S; Cozza G; Magro M; Fedele G; Vianello F; Venerando A
Int J Biol Macromol; 2020 Dec; 165(Pt A):701-712. PubMed ID: 33010276
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of CK2 in acute and chronic leukemias.
Buontempo F; McCubrey JA; Orsini E; Ruzzene M; Cappellini A; Lonetti A; Evangelisti C; Chiarini F; Evangelisti C; Barata JT; Martelli AM
Leukemia; 2018 Jan; 32(1):1-10. PubMed ID: 28951560
[TBL] [Abstract][Full Text] [Related]
9. [Casein kinase 2, the versatile regulator of cell survival].
Volodina IuL; Shtil' AA
Mol Biol (Mosk); 2012; 46(3):423-33. PubMed ID: 22888632
[TBL] [Abstract][Full Text] [Related]
10. Addiction to protein kinase CK2: a common denominator of diverse cancer cells?
Ruzzene M; Pinna LA
Biochim Biophys Acta; 2010 Mar; 1804(3):499-504. PubMed ID: 19665589
[TBL] [Abstract][Full Text] [Related]
11. Protein kinase CK2 as a druggable target.
Sarno S; Pinna LA
Mol Biosyst; 2008 Sep; 4(9):889-94. PubMed ID: 18704226
[TBL] [Abstract][Full Text] [Related]
12. Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies.
Gowda C; Sachdev M; Muthusami S; Kapadia M; Petrovic-Dovat L; Hartman M; Ding Y; Song C; Payne JL; Tan BH; Dovat S
Curr Pharm Des; 2017; 23(1):95-107. PubMed ID: 27719640
[TBL] [Abstract][Full Text] [Related]
13. CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation.
Perea SE; Baladrón I; Valenzuela C; Perera Y
Semin Oncol; 2018 Jan; 45(1-2):58-67. PubMed ID: 30318085
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase CK2 inhibitors: a patent review.
Cozza G; Pinna LA; Moro S
Expert Opin Ther Pat; 2012 Sep; 22(9):1081-97. PubMed ID: 22908959
[TBL] [Abstract][Full Text] [Related]
15. Casein kinases as potential therapeutic targets.
Cozza G; Pinna LA
Expert Opin Ther Targets; 2016; 20(3):319-40. PubMed ID: 26565594
[TBL] [Abstract][Full Text] [Related]
16. ATP site-directed inhibitors of protein kinase CK2: an update.
Sarno S; Papinutto E; Franchin C; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Orzeszko A; Zanotti G; Battistutta R; Pinna LA
Curr Top Med Chem; 2011; 11(11):1340-51. PubMed ID: 21513497
[TBL] [Abstract][Full Text] [Related]
17. Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2.
Duncan JS; Litchfield DW
Biochim Biophys Acta; 2008 Jan; 1784(1):33-47. PubMed ID: 17931986
[TBL] [Abstract][Full Text] [Related]
18. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance.
D'Amore C; Borgo C; Sarno S; Salvi M
Cell Oncol (Dordr); 2020 Dec; 43(6):1003-1016. PubMed ID: 33052585
[TBL] [Abstract][Full Text] [Related]
19. Optimization of pyrazolo[1,5-a]pyrimidines lead to the identification of a highly selective casein kinase 2 inhibitor.
Krämer A; Kurz CG; Berger BT; Celik IE; Tjaden A; Greco FA; Knapp S; Hanke T
Eur J Med Chem; 2020 Dec; 208():112770. PubMed ID: 32883634
[TBL] [Abstract][Full Text] [Related]
20. Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.
Jabor Gozzi G; Bouaziz Z; Winter E; Daflon-Yunes N; Aichele D; Nacereddine A; Marminon C; Valdameri G; Zeinyeh W; Bollacke A; Guillon J; Lacoudre A; Pinaud N; Cadena SM; Jose J; Le Borgne M; Di Pietro A
J Med Chem; 2015 Jan; 58(1):265-77. PubMed ID: 25272055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
